Literature DB >> 8581289

Lack of effect of TNF antibodies on the cardiovascular sequelae of lipopolysaccharide infusion in conscious rats.

J Waller1, S M Gardiner, J Jose, T Bennett.   

Abstract

1. The aims of the present study were to determine the profile of tumour necrosis factor (TNF) release, and the effect of monoclonal antibodies to TNF, on the changes in regional haemodynamics and the responses to vasodilator and vasoconstrictor challenges, during a continuous 24 h low dose infusion of lipopolysaccharide (LPS) in conscious rats. 2. Male Long Evans rats were chronically instrumented for measurement of regional haemodynamics (renal, superior mesenteric and hindquarters) and were challenged with 3 min infusions of acetylcholine (22 nmol min-1), methoxamine (120 nmol min-1), salbutamol (0.83 nmol min-1) and bradykinin (14.4 nmol min-1). The rats were given either saline, or the TNF antibodies, TN3g1 or TN3g2a, 1 h before the start of a continuous infusion of LPS (150 micrograms kg-1 h-1) and were subsequently re-tested with the vasodilator and vasoconstrictor challenges 2, 6 and 24 h after the start of the LPS infusion. 3. Prior to infusion of LPS, TNF was not detectable in the plasma. During continuous infusion of LPS there was a transient elevation in plasma TNF levels, reaching a maximum (approximately 2300 pg ml-1) after approximately 1 h, and returning to undetectable levels after approximately 3 h of LPS infusion. 4. In the saline pretreated group, after 1-2 h of LPS infusion, there was a small hypotension and a marked renal vasodilation; 6 h after the start of LPS infusion there was a minor elevation in MAP above control levels, renal vasodilatation was maintained and a hindquarters vasoconstriction occurred; after 24 h of LPS infusion, there was a hypotension and renal and hindquarters vasodilatation. There were significant reductions in the tachycardic and renal vasodilator responses and an enhanced depressor response to acetylcholine after 24 h of LPS infusion. LPS infusion also caused a generalized hyporesponsiveness to the cardiovascular effects of methoxamine and salbutamol. The major changes in response to bradykinin were reduced tachycardic and enhanced depressor responses throughout the LPS infusion, a biphasic decrease and increase in renal conductance and enhanced hindquarters vasodilatation at 24 h. 5. Pretreatment with either TN3g1 or TN3g2a antibodies had no major effects on the changes in resting haemodynamics, or on the changes in response to methoxamine, salbutamol or bradykinin challenges during LPS infusion. However, the tachycardic responses to acetylcholine were generally preserved, and its hypotensive effect after 24 h of LPS infusion was not enhanced after TN3g1 or TN3g2a pretreatment. Thus, despite substantial, but transient, elevation of plasma TNF levels during continuous LPS infusion, it appears that the majority of cardiovascular changes were dependent on factors other than plasma TNF.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8581289      PMCID: PMC1909041          DOI: 10.1111/j.1476-5381.1995.tb15100.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  42 in total

1.  Can pulsed Doppler technique measure changes in aortic blood flow in conscious rats?

Authors:  S M Gardiner; A M Compton; T Bennett; C J Hartley
Journal:  Am J Physiol       Date:  1990-08

2.  Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors.

Authors:  K C Sheehan; N H Ruddle; R D Schreiber
Journal:  J Immunol       Date:  1989-06-01       Impact factor: 5.422

3.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia.

Authors:  K J Tracey; Y Fong; D G Hesse; K R Manogue; A T Lee; G C Kuo; S F Lowry; A Cerami
Journal:  Nature       Date:  1987 Dec 17-23       Impact factor: 49.962

4.  Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha).

Authors:  L B Hinshaw; P Tekamp-Olson; A C Chang; P A Lee; F B Taylor; C K Murray; G T Peer; T E Emerson; R B Passey; G C Kuo
Journal:  Circ Shock       Date:  1990-03

5.  Failure of tumor necrosis factor to produce hypotensive shock in the absence of endotoxin.

Authors:  I R Neilson; K A Neilson; E J Yunis; M I Rowe
Journal:  Surgery       Date:  1989-08       Impact factor: 3.982

6.  Control of regional blood flow by endothelium-derived nitric oxide.

Authors:  S M Gardiner; A M Compton; T Bennett; R M Palmer; S Moncada
Journal:  Hypertension       Date:  1990-05       Impact factor: 10.190

7.  Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice.

Authors:  J L Rothstein; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

8.  Recombinant human tumor necrosis factor produces hemodynamic changes characteristic of sepsis and endotoxemia.

Authors:  W J Schirmer; J M Schirmer; D E Fry
Journal:  Arch Surg       Date:  1989-04

9.  Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-alpha in experimental gram-negative shock.

Authors:  A T Silva; K F Bayston; J Cohen
Journal:  J Infect Dis       Date:  1990-08       Impact factor: 5.226

10.  Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock.

Authors:  C Natanson; P W Eichenholz; R L Danner; P Q Eichacker; W D Hoffman; G C Kuo; S M Banks; T J MacVittie; J E Parrillo
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

View more
  7 in total

1.  Haemodynamic effects of the bacterial quorum sensing signal molecule, N-(3-oxododecanoyl)-L-homoserine lactone, in conscious, normal and endotoxaemic rats.

Authors:  S M Gardiner; S R Chhabra; C Harty; P Williams; D I Pritchard; B W Bycroft; T Bennett
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

2.  Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious rats.

Authors:  S M Gardiner; T R Auton; M R Downham; H L Sharp; P A Kemp; J E March; H Martin; P J Morgan; A Rushton; T Bennett; J F Glover
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

3.  A potential role for Akt/FOXO signalling in both protein loss and the impairment of muscle carbohydrate oxidation during sepsis in rodent skeletal muscle.

Authors:  Hannah Crossland; Dumitru Constantin-Teodosiu; Sheila M Gardiner; Despina Constantin; Paul L Greenhaff
Journal:  J Physiol       Date:  2008-09-25       Impact factor: 5.182

4.  Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man.

Authors:  M R Downham; T R Auton; A Rosul; H L Sharp; L Sjöström; A Rushton; J P Richards; T G K Mant; S M Gardiner; T Bennett; J F Glover
Journal:  Br J Clin Pharmacol       Date:  2003-11       Impact factor: 4.335

5.  Temporal changes in the involvement of pyruvate dehydrogenase complex in muscle lactate accumulation during lipopolysaccharide infusion in rats.

Authors:  N Alamdari; D Constantin-Teodosiu; A J Murton; S M Gardiner; T Bennett; R Layfield; P L Greenhaff
Journal:  J Physiol       Date:  2008-01-24       Impact factor: 5.182

6.  Inflammation-mediated muscle metabolic dysregulation local and remote to the site of major abdominal surgery.

Authors:  Krishna K Varadhan; Dumitru Constantin-Teodosiu; Despina Constantin; Paul L Greenhaff; Dileep N Lobo
Journal:  Clin Nutr       Date:  2017-11-02       Impact factor: 7.324

7.  Effects of endotoxaemia on protein metabolism in rat fast-twitch skeletal muscle and myocardium.

Authors:  Andrew J Murton; Nima Alamdari; Sheila M Gardiner; Dumitru Constantin-Teodosiu; Robert Layfield; Terence Bennett; Paul L Greenhaff
Journal:  PLoS One       Date:  2009-09-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.